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Available online 20 December 2018Background: Cyclin-dependent protein kinase 9 (CDK9) has been shown to play an important role in the
pathogenesis of malignant tumors. However, the expression and function of CDK9 remain unknown in osteosar-
comas. The purpose of this study is to assess the expression, function and clinical prognostic relationship of CDK9
in osteosarcomas.
Methods: A tissue microarray of 70 patient specimens was analyzed by immunohistochemistry to measure CDK9
expression, which was further investigated for correlation with patient clinical characteristics. CDK9 expression
in osteosarcoma cell lines and patient tissues was also evaluated by Western blotting. CDK9-specific siRNA and
the CDK9 inhibitor were applied to determine the effect of CDK9 inhibition on osteosarcoma cell proliferation
and anti-apoptotic activity. The clonogenicity and migration activity were also examined using clonogenic and
wound healing assays. A 3D cell culture model was performed to mimic the in vivo osteosarcoma environment
to further validate the effect of CDK9 inhibition on osteosarcoma cells.
Findings: We demonstrated that higher CDK9-expression is associated with significantly shortened patient
survival by immunohistochemistry. Expression of CDK9 is inversely correlated to the percent of tumor necrosis
post-neoadjuvant chemotherapy, which is the most important predictive factor of disease outcome for osteosar-
coma patients. Knockdown of CDK9with siRNA and inhibition of CDK9 activity with inhibitor decreased cell pro-
liferation and induced apoptosis in osteosarcoma.
Interpretation: High expression of CDK9 is an independent predictor of poor prognosis in osteosarcoma patients.
Our results suggest that CDK9 is a novel prognosticmarker and a promising therapeutic target for osteosarcomas.ry, Depa
geles, 61
. This is©2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Apoptosis1. Introduction
Osteosarcoma is the most common malignant tumor that affects
children, adolescents, and young adults [1]. It is responsible for 20% of
all primary bone sarcomas [2]. Before 1970, treatment for osteosarcoma
primarily involved surgical resection. Chemotherapy has dramatically
improved 5-year survival for patients with localized osteosarcoma
from b20% to over 65% following the advent of multiagent regimens
[3]. However, recurrent and metastatic osteosarcoma have retained a
high mortality rate, with patient survival usually less than one year
[1,4,5]. In the last 30 years, the treatment and survival rates of osteosar-
coma patients have shown very little improvement. Therefore, the
development of novel therapeutic strategies for the treatment of osteo-
sarcoma remains an important and unmet clinical need.rtment of Orthopaedic
5 Charles E. Young Dr.
an open access article underCyclin-dependent kinases (CDKs) are members of a complex family
of heterodimeric serine/threonine protein kinases and are involved in
critical cellular processes, including in cellular DNA transcription and
cell-cycle progression, among others [6]. Mammalian cells contain at
least 20 different CDKs, but only a few subsets of CDK–Cyclin complexes
are directly associated with cell-cycle progression. Previous studies
have demonstrated that many CDKs are associated with tumorigenesis
and progression of different cancers, including osteosarcoma [7–13].
Therefore, pharmacological inhibition of CDKs has been considered as
an attractive option for treating a number of human malignancies.
Palbociclib (IBRANCE®), a dual CDK4/6 inhibitor, has already received
U.S FDA approval for the treatment of breast cancer [14,15]. Palbociclib
has also demonstrated promising antitumor potential both as a mono-
therapy and in combination in many preclinical studies and clinical tri-
als for a number of other cancer types [16–18].
Recently, cyclin-dependent protein kinase 9 (CDK9) has been shown
to play an essential role in acute myeloid leukemia, breast cancer, mel-
anoma, prostate cancer and lung cancer [12,19–25]. CDK9 and cyclin T
complex, which is a component of the positive transcription elongationthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
CDK9 has also emerged as an important therapeutic target in can-
cer, due to its crucial role in RNA transcription, elongation and
other cellular processes. In complex with regulatory cyclins,
CDK9 drives the transcription of global (non-ribosomal) genes, in-
cluding genes that are regulated by super enhancers, a large clus-
ter of DNA regulatory element enhancers. As a consequence,
CDK9 is involved in cell cycle progression, growth, proliferation,
differentiation, and apoptosis. Dysregulation of CDK9 has been
observed in a number of human solid tumors, including prostate
cancer, neuroblastoma, hepatocellular carcinoma and lymphoma,
but remains to be investigated in osteosarcoma.
Added value of this study
In this study, we demonstrate that osteosarcoma patients with
high CDK9 tumor-expression levels have significantly shorter sur-
vival than patients with low CDK9 expression. In addition to this,
the expression of CDK9 is inversely correlated to the percent of
tumor necrosis that occurs post-neoadjuvant chemotherapy. Inhi-
bition of CDK9 either by siRNA or an inhibitor, can abrogate oste-
osarcoma cell growth or induce apoptosis both in vitro and mimic
in vivo. Collectively, these findings suggest that CDK9 is a critical
component of osteosarcoma cell growth, proliferation and migra-
tion. Therefore, CDK9 is an attractive and promising molecular
biomarker and therapeutic target for patients with osteosarcoma.
Implications of all the available evidence
Osteosarcomas are currently treated using chemotherapy regi-
mens established over 30 years ago. Although chemotherapy
hasdramatically improved their 5-year survival, recurrent andmet-
astatic osteosarcoma still have a high mortality rate. The develop-
ment of novel therapeutic strategies for the treatment of
osteosarcoma remains an important and unmet clinical need. Our
study demonstrates that the expression of CDK9 is associated
with the clinical prognosis of patients with osteosarcoma. CDK9
plays an important role in osteosarcoma cell growth and prolifera-
tion. A recent study has demonstrated that the treatment of CDK9
overexpressing patient-derived tumor xenograft (PDTX) osteosar-
coma models, with the CDK inhibitor AT7519, resulted in de-
creased tumor growth. Similarly, another novel highly selective
CDK9 inhibitor, MC180295, has demonstrated broad anti-
cancer activity in vitro and is effective in in vivo cancer models.
These findings suggest that CDK9 is a promising molecular target
in osteosarcoma.
183H. Ma et al. / EBioMedicine 39 (2019) 182–193factor b (P-TEFb), promotes release of paused RNA polymerase II
(RNAPII) into elongation process [26]. CDK9 is expressed in two iso-
forms, a lighter 42 kDa isoform and a heavier 55 kDa isoform, the latter
is translated from the same mRNA but at an upstream transcriptional
start site of the 42 kDa protein [27]. Compared with the lighter isoform,
the 55 kDa protein has an additional 117 amino acids at theN-terminus.
These two isoforms of CDK9 have mostly been attributed to the regula-
tion of transcription but not cell-cycle progression [27,28]. Both iso-
forms have been shown to be expressed in human cancer cell lines
and in normal tissues. CDK9 has been reported to regulate RNAPII-
associated transcription by phosphorylating the large subunit of
RNAPII, at the C-terminal domain (CTD) [19,29]. RNAPII suppressed byCDK9 inhibition has been shown to block transcriptional elongation
leading to oppression of short-living anti-apoptotic proteins, such as
MCL-1, thereby promoting the apoptosis of tumor cells [30]. Accord-
ingly, targeting CDK9, or blocking its pathway of transcription, offers a
potentially effective therapy for malignant tumors (Supplementary
Fig. S1). However, the relationship between CDK9 expression and
clinical prognosis, and the therapeutic potential of targeting CDK9 in
osteosarcoma patients remains to be elucidated. This prompted us to
evaluate the role of CDK9 in osteosarcoma.
This is the first study to examine the expression of CDK9 in osteosar-
coma patient specimens and correlate this to post-neoadjuvant chemo-
therapy tumor necrosis as well as the clinical prognosis of the patients.
We also investigated the role of CDK9 in cell proliferation, colonization
and migration in osteosarcoma cells.
2. Materials and methods
2.1. Osteosarcoma sample collection and tissue microarrays (TMA)
A total of 70 osteosarcoma specimens with formalin fixed paraffin-
embedded (FFPE) blocks and 8 fresh tissue samples were obtained
from patients who were diagnosed with osteosarcoma and who had re-
ceived preoperative chemotherapy and surgical treatment at the Ortho-
paedic Department of Massachusetts General Hospital (MGH) between
1993 and 2010. Clinical information was also collected, including age,
gender, tumor location, disease status, and follow-up time. The samples
included 46 (65.7%) males and 24 (34.3%) females, with the mean age
of 34.1 years old (range: 6–77 years old). All osteosarcoma patients
were followed up for a mean period of 81.1 months after surgery
(range: 1–273months). The TMAof osteosarcoma FFPE blockswere pro-
vided by the Sarcoma Tissue Bank in MGH. To ensure that the selection
included the core of the tumor, three sites of each FFPE block were se-
lected for assembling the recipient master block. The TMA was
constructed by the Tissue Microarray and Imaging Core at the Dana-
Farber/Harvard Cancer Center. Representative triplicate 0.5 mm-
diameter corebiopsies of each tissueblockwereobtained through thepa-
thology reports and reading of corresponding Hematoxylin and eosin
(HE)-stained slides by apathologist. The studywas approvedby the Part-
nersHumanResearchCommittee (#: 2007P-002464). All patients signed
a consent form for their clinical information to be used for this research.
2.2. Immunohistochemistry (IHC)
The expression of CDK9 was determined using IHC assays according
to the manufacturer's instructions (Cell Signaling Technology, Beverly,
MA, USA). In brief, the paraffin-embedded slides were baked for 1 h at
60 °C before xylene deparaffinization and subsequent rehydration
through graded ethanol (100% and 95%). 3% hydrogen peroxide was
used to quench endogenous peroxidase activity after heated epitope re-
trieval. Following this, the slide was blocked for 1 h with normal goat
serum, and then incubated with polyclonal rabbit antibody to human
CDK9 (Cell Signaling Technology, catalog #2316S, 1:50 dilution, in 1%
bovine serum albumin PBS) overnight in a humidified chamber set at
4 °C. SignalStain® Boost Detection Reagent (Cell Signaling Technology)
and SignalStain®DAB (Cell Signaling Technology) were then utilized to
detect the bound antibody. A hematoxylin QS (Vector Laboratories, Bur-
lingame, CA) counterstainwas used to obtain clearer images of the oste-
osarcoma cell nuclei before final long-term preservation using
VectaMount AQ (Vector Laboratories) sectionmounting. Even in the ab-
sence of CDK4 antibody binding, the TMA slides were stained to reveal
any nonspecific secondary antibody reactions.
2.3. Analysis of immunohistochemistry staining
Two independent pathologists, who were blinded to patient data
and tumor characteristics, viewed and scored the immunostained
184 H. Ma et al. / EBioMedicine 39 (2019) 182–193slides. CDK9 expression was subsequently divided up into 6 groups
based on the percentage of cells showing positive nuclear staining: 0,
no nuclear staining; 1+, b10% of positive cells; 2+, 10%–25% of positive
cells; 3+, 26%–50% of positive cells; 4+, 51%–75% of positive cells; 5+,
N75% of positive cells. The low-CDK9 expression subset included groups
0; 1+ and 2+, while the high-CDK9 expression subset included groups
3+; 4+and5+. The tumor necrosis datawas collected from the clinical
data, and grouped according to the percent of tumor tissue necrosis of
pathological specimens. Data was divided into two groups; good re-
sponse: ≥ 90% necrosis; poor response: b90% necrosis. CDK9 staining
images were obtained using a Nikon Eclipse Ti\\U fluorescence micro-
scope (Diagnostic Instruments Inc., NY, USA) with a SPOT RT™ digital
camera (Diagnostic Instruments Inc.).
2.4. Human osteoblast and osteosarcoma cell lines and cell culture
The human osteoblast cell line HOB-c was purchased from
PromoCell GmbH (Heidelberg, Germany). Osteoblast cell lineswere cul-
tured in osteoblast growthmedium (PromoCell). Human osteosarcoma
cell lines U2OS, MG63, MNNG/HOS, Saos-2, and 143B were obtained
from the American Type Culture Collection (Rockville, MD). Osteosar-
coma cell lines KHOS, KHOSR2, and U2OSR2 were provided by Dr.
Efstathios Gonos (Institute of Biological Research & Biotechnology, Ath-
ens, Greece). All osteosarcoma cell lines were cultured at 37 °C in a hu-
midified 5% CO2 atmosphere in RPMI 1640 (GE Healthcare Life Sciences,
Logan, Utah, USA) supplemented with 10% fetal bovine serum (Sigma-
Aldrich, MO, USA) and 1% penicillin/streptomycin.
2.5. Protein preparation and western blotting
1× RIPA lysis buffer (Sigma-Aldrich) and protease inhibitor cocktail
tablets (Roche Applied Science, IN, USA)were used to extract protein ly-
sates from the cells or tissues. The protein lysate concentrations were
then determined using the DC™ protein assay reagents (BIORAD, Her-
cules, CA, USA) and a spectrophotometer SPECTRA max 340PC (Molec-
ular Devices, Inc., CA, USA). Western blotting was performed using
similar methods to those previously described [13]. In short, an SDS-
PAGE gel was used to run the denatured proteins before they were
transferred to nitrocellulose membranes. The membranes were incu-
bated with monoclonal rabbit antibodies to human RNAPII ser2
(1:1000 dilution, Abcam, San Francisco, California, USA), CDK9, MCL-1,
BIRC5 (1:1000 dilution, Cell Signaling Technology), and monoclonal
mouse antibodies to human RNAPII total (1:1000 dilution, Abcam), Tu-
bulin (1:1000 dilution, Cell Signaling Technology) at 4 °C overnight after
they were blocked in 5% nonfat milk for 1 h. Following incubation with
the primary antibody, TBST was then used as a membrane wash (3
times, 5 min, room temperature). Next, goat anti-rabbit IRDye 800CW
(926–32,211, 1:5000 dilution) or goat anti-mouse IRDye 680LT second-
ary antibody (926–68,020, 1:15000 dilution) (Li-COR Biosciences, NE,
USA) was applied for 2 h at room temperature followed by another
TBST membrane wash (3 times, 5 min, room temperature). Bands
were detected using an Odyssey Infrared FluorescentWestern Blots Im-
aging System from Li-COR Bioscience (Lincoln, NE, USA) and Odyssey
software 3.0 was used to quantify the bands.
2.6. Immunofluorescence assay
The cultured osteosarcoma cell lines were used in the immunofluo-
rescence assays. The cells were grown for three days in 6-well plates
and fixed with 4% paraformaldehyde for 15 min before being perme-
abilized with ice-cold methanol and blocked with 1% BSA. A CDK9
primary antibody (1:200 dilution, Cell Signaling Technology), and
β-Actin (1:500 dilution, Sigma-Aldrich) were incubated with the cells
at 4 °C overnight. The next day cells were incubated for an additional
1 h with Alexa Fluor 488 (Green) conjugated goat anti-rabbit antibody
or Alexa Fluor 594 (red) goat anti-mouse antibody (Invitrogen, NY,USA). Cells were imaged using a Nikon Eclipse Ti\\U fluorescence mi-
croscope (Diagnostic Instruments Inc., NY, USA) equipped with a SPOT
RT™ digital camera.
2.7. Knockdown of CDK9 by siRNA Transfection and MTT Assay
Knockdown of CDK9 in osteosarcoma cells was performed by a spe-
cific siRNA transfection. In brief, U2OS and KHOS cells were grown at a
density of 2 × 103 cells/well in 96-well plates or at a density of 4
× 104 cells/well in 12-well plates and transfected with increasing con-
centrations (0, 10, 30, 60 nM) of synthesized CDK9 siRNA (5’-GCUGCU
AAUGUGCUUAUCA-3′) (Sigma-Aldrich) using the Lipofectamine
RNAiMax reagent (Invitrogen) according to themanufacturer's instruc-
tions. Nonspecific siRNA (60 nM) was used as a negative control. Three
or five days after transfection of the CDK9 siRNA, the proteins of U2OS
and KHOS cell were extracted for protein measurement with Western
blotting or assessment of cellular proliferation by MTT assays. At the
end of the 5-day cell treatment, 20 μL of MTT (5 mg/mL, Sigma-
Aldrich) was added to each well of the 96-well plates. After incubating
at 37 °C in a humidified 5% CO2 atmosphere for 4 h, the resulting
formazan product was solubilized with 100 μL of acid isopropanol and
the absorbance was measured at a wavelength of 490 nm on the
SpectraMax Microplate® Spectrophotometer (Molecular Devices LLC,
Sunnyvale, CA).
2.8. CDK9 suppression by LDC000067 inhibitor treatment and MTT assay
The novel highly selective CDK9 inhibitor, LDC000067 (abbreviated
as LDC067; Sigma-Aldrich), has been verified at a concentration of 10
μM to inhibit the effects of CDK9 in several cancer cell lines [31]. Here,
U2OS and KHOS cells were seeded into 96-well plates at a density of 4
× 103 cells/well or 6-well plates at a density of 6 × 105 cells/well and in-
cubated with increasing concentrations (0, 2.5, 5, 10, 20 μM) of LDC067
for 2, 3, or 5 days prior to subsequent experiments. After LDC067 treat-
ment for 5 days, the cell proliferation of U2OS and KHOS was investi-
gated using the MTT assay (see above mentioned experimental
procedure). Meanwhile, in order to detect the morphological changes
of U2OS and KHOS cells, a Nikon microscope (Diagnostic Instruments
Inc., NY, USA) was used after 3 days of LDC067 treatment.
2.9. Clonogenic assays
The clonogenic assay is a well-established in vitromethod for evalu-
ating the viability and proliferation capabilities of cells. Osteosarcoma
cells, U2OS and KHOS, were seeded at 150 cells/well in the 12-well
plates and treatedwith the CDK9 inhibitor, LDC067, at different concen-
trations (0, 5, 10 μM), and incubated at 37 °C for 12 days. Colonies were
subsequently fixed with methanol for 10 min, and then washed three
times with PBS before staining with 10% Giemsa stain (Sigma-Aldrich)
for 20 min. The cells were washed with flowing water and allowed to
dry. Pictures of the stained colonies were captured using digital camera
(Olympus, Tokyo, Japan).
2.10. Cell wounding healing migration assays
Wound healing assays were applied to test cell migration activities.
U2OS and KHOS cells were seeded into 6-well plates at a density of 4
× 105 cells per well and incubated overnight. A sterile 10 μL tip was
then used to scrape two parallel lines within the adherent cell layer.
Next, 10 μM of LDC067 was added and left to incubate for 72 h in a
low-serum medium containing 2% FBS. Wounds were photographed
using a Nikon microscope (Diagnostic Instruments Inc., NY, USA) with
Zen Imaging software after 0, 24, 48, and 72 h of the LDC067 treatment.
The distance between the two edges of the scratch, at five distinct sites
of each image, was used to measure the width of the wounds. The fol-
lowing formula was applied to measure the cell migration distance:
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point) / 2.
2.11. Three-dimension(3D) cell culture
A 3D cell culture is an improvedmethod and amore accurate model
that canmimic the in vivo environment to evaluate the behavior of can-
cer cell growth [32]. Spheroid formation of the osteosarcoma cell lines,
U2OS and KHOS, was established in 24-well VitroGel™ 3D cell culture
plates with a density of 2 × 105 cells/well, according to themanufactur-
er's protocol (TheWell Bioscience Inc., NJ, USA). Immediately following
this, 10 μM of LDC067 was added into the cell medium. Osteosarcoma
cells without treatmentwere considered as the blank control. The plates
were incubated at 37 °C in a humidified 5% CO2 atmosphere. Medium
was changed every 24–48 h to provide enough nutrients for the cells
and to prevent an osmolality shift in the medium. The spheroids were
photographed under a Nikon microscope (Diagnostic Instruments
Inc.) equipped with the Zen Imaging software every 2 days. At the
point of 12 days, the spheroids were harvested from the bottom side
of the plate by gently pipetting 100 μL PBS into each well. After
15 min of incubation with 0.25 μM Calcein AM (Invitrogen™, Oregon,
USA), the spheroids were imaged on the Nikon Eclipse Ti\\U fluores-
cence microscope (Diagnostic Instruments Inc.) equipped with a SPOT
RT™ digital camera. The diameter of spheroids was measured three
times using software ImageJ.
2.12. Statistical analysis
GraphPad Prism 7 software was used for statistical analyses. Inde-
pendent two-tailed Student t-tests were performed for independent
data to determine the statistical significance. One-way ANOVA tests
were performed for multiple comparisons. Comparison of differences
in survival curves was analyzed by Kaplan-Meier plots and log-rank
tests. The χ2 test was used to evaluate the relationship between CDK9
expression and osteosarcoma clinical-pathological parameters. Prog-
nostic factors associated with overall survival were analyzed through
the Cox proportional hazards regression model, in a stepwise manner.
Only those factors that were statistically significant (P b .05) in the uni-
variate survival analysis were involved in the multivariate analysis. The
correlations analysis was investigated by a Spearman's rank correlation.
All results were presented asmean±SD, and P values b.05was deemed
statistically significant.
3. Results
3.1. CDK9 expression is associatedwith the clinicopathological features and
clinical prognosis of osteosarcoma patients
We first evaluated the CDK9 expression of osteosarcoma patient
samples and analyzed if this could be correlated to their pathological
characteristics, as well as the patient clinical prognosis. Of the available
patient samples, 67 of 70 (95.7%) tissues exhibited CDK9 immunostain-
ing in the cell nucleus, ranging from 0 staining (3 of 70, 4.3%); 1+ stain-
ing (15 of 70, 21.4%), 2+ staining (5 of 70, 7.1%), and 3+ staining (11 of
70, 15.7%), 4+ staining (9 of 70, 12.8%), 5+ staining (27 of 70, 38.6%)
(Fig. 1A and B, Supplementary Table S1). The stained specimens were
subdivided into two categories: ≤2+were defined as low CDK9 expres-
sion (32.9%) and ≥3+ were defined as high CDK9 expression (67.1%)
(Fig. 1A and C, Table 1).
We also compared patient prognosis with the expression of CDK9.
There was a significant difference in CDK9 expression between primary
tumor tissues (patients without metastatic/recurrent disease) and tis-
sues taken from patients with metastatic disease (P b .0001, based on
the Independent two-tailed Student t-test) (Fig. 2A). Based on the pa-
tient follow-up data, the CDK9 expression was significantly higher in
the osteosarcoma tissues from the patients who developed metastaticdisease compared with those patients who did not (P = .0064, based
on the Independent two-tailed Student t-test) (Fig. 2B). We also found
that the expression of CDK9 in patients who did not survive (non-sur-
vival) was significantly higher than those who did survive (survival)
(P = .0123, based on the Independent two-tailed Student t-test)
(Fig. 2C). Further analysis showed that CDK9 expression had no rela-
tionship to other clinical pathological features of the patients, including
age (P=.1719, based on the χ2 test), gender (P=.6799, based on the χ2
test), and tumor site (P= .9945, based on the χ2 test) (Table 1).
Next, we further evaluated the association between CDK9 expres-
sion and other clinical outcomes of osteosarcoma patients, including
overall patient survival and disease-free survival. The Kaplan-Meier
analysis revealed that patients with high CDK9 expressing tumors had
significantly worse overall survival rates compared to patients with
low CDK9 expressing tumors (P = .0002, based on the log-rank test)
(Fig. 2D). Similarly, patients with high CDK9 expression had signifi-
cantly worse disease-free survival rates than the patients with low
CDK9 expression (P= .0152, based on the log-rank test) (Fig. 2E). Fur-
thermore, to confirmwhether CDK9 expression is an independent prog-
nostic factor for osteosarcoma patients, we applied a Cox regression
analysis. In the univariate Cox regression analysis, overexpression of
CDK9, presence of metastatic disease, and the response to preoperative
chemotherapy were all associated with a shorter survival rate in osteo-
sarcoma patients. However, other clinicopathological features showed
no prognostic correlations (Table 2). Notably, the analysis of multivari-
ate Cox regression indicated that high CDK9 expression was an inde-
pendent predictor for survival of osteosarcoma patients (P = .004,
based on the Cox proportional hazards regression model) (Table 2).
These results demonstrated that CDK9 expression independently pre-
dicts osteosarcoma patient outcomes.3.2. CDK9 expression is inversely correlated to percent of tumor necrosis
post-neoadjuvant chemotherapy in osteosarcoma patients
It is well known that the percent of necrosis after neoadjuvant che-
motherapy is the most important predictive factor of disease outcome
for osteosarcoma patients [33–35]. Significant necrosis is associated
with better disease-free survival and overall survival. First, we evalu-
ated whether CDK9 expression is associated with the degree of necrosis
as determined by the percent of tumor necrosis on histological exami-
nation of osteosarcoma tumor specimens. Among the 70 patient sam-
ples, the percent of tumor necrosis post-neoadjuvant chemotherapy
data was available for 41 specimens. Eight tumor tissues demonstrated
≥90% necrosis (good responders) and 33 patients showed b90% necrosis
(poor responders) after neoadjuvant chemotherapy. Patients with a
poor response had significantly higher CDK9 expression compared
with thosewho had a good response (P= .0010, based on the Indepen-
dent two-tailed Student t-test) (Fig. 3A and Supplementary Table S2). In
addition, there was a significant difference in the overall survival rate
between good responders and poor responders (P = .0018, based on
the log-rank test) (Fig. 3B). We further compared the relationship be-
tween CDK9 expression, the percent of tumor necrosis and overall sur-
vival in these osteosarcoma patients. The data revealed the overall
survival of patients is inversely correlated to CDK9 expression levels
(P b .0001, r = −0.6422, based on the Spearman's rank correlation)
(Fig. 3C). In contrast, as anticipated, the overall survival of patients is di-
rectly correlated with the increase of the percent of tumor necrosis (P b
.0001, r= 0.6630, based on the Spearman's rank correlation) (Fig. 3D)
We also evaluated if high CDK9 expression is related to a decrease in
the necrosis of osteosarcoma tissues. Indeed, linear regression analysis
demonstrated that the expression of CDK9 is inversely proportional to
the percent of tumor necrosis in osteosarcoma tissues (P b .0001, r =
−0.5884, based on the Spearman's rank correlation) (Fig. 3E). These re-
sults indicate that CDK9expression can act as an indirect indicator of the
percent of tumor necrosis post-neoadjuvant therapy in osteosarcomas.
Fig. 1. Evaluation of CDK9 expression and staining in an osteosarcoma TMA by immunohistochemistry. (A) Representative images of different immunohistochemistry staining intensities
of CDK9 and HE staining are shown in osteosarcoma tissues. According to the CDK9 staining in the tumor samples, the staining patterns were divided into 6 groups: no positive staining
(0); b10% positive cells (1+); 10–25% positive cells (2+); 26–50% positive cells (3+); 51–75% positive cells (4+); N75% positive cells (5+). (Original magnification, 400×; Scale bar, 50
μm). (B) Pie chart representing relative frequency of different CDK9 expression levels in osteosarcoma tissue microarrays. (C) Tumors with the staining score of ≤2+were defined as low
CDK9 expression group (blue), ≥3+ were defined as the high CDK9 expression group (green). Pie chart representing relative frequency of the two groups in osteosarcoma tissue
microarrays.
186 H. Ma et al. / EBioMedicine 39 (2019) 182–1933.3. CDK9 is highly expressed in human osteosarcoma cell lines and tissues
To determine the potential role of CDK9 in human osteosarcoma
cells, we first examined the expression of CDK9 in human osteosarcoma
cell lines. Western blotting analysis showed that CDK9 is highly
expressed in osteosarcoma cell lines (U2OS, U2OSR2, KHOS, KHOSR2,
MG63, Saos-2, 143B and MNNG/HOS), whereas the expression of
CDK9 is markedly lower in the normal osteoblast cell line (HOB-c)
(Fig. 4A and B). In order to preclude the possibility that CDK9 expression
is an artifact induced by in vitro propagation, we further evaluated the
expression of CDK9 in eight osteosarcoma fresh specimens. The results
demonstrated that CDK9 is highly expressed in themajority of osteosar-
coma tissues (Fig. 4C and D). There are 2 known isoforms of the CDK9
protein, our study found both CDK9 42 kDa and CDK9 55 kDa isomers
had variable expression in osteosarcoma cell lines and osteosarcoma tis-
sues. The 42 kDa form is predominantly overexpressed, thus the 42 kDa
bandwas used for the quantification of CDK9 expression (Fig. 4B andD).
We also explored the expression of CDK9 and confirmed its cellular lo-
calization in osteosarcoma cells by immunofluorescence in U2OS and
KHOS cell lines. We found that the CDK9 protein was mainly localized
to the cell nucleus (Fig. 4E). Collectively, these results are consistentwith the TMA data showing marked CDK9 expression in osteosarcoma
samples (Fig. 1A).3.4. CDK9 knockdown by siRNA decreased human osteosarcoma cell
proliferation
In order to validate the role of CDK9 in osteosarcoma cell prolifera-
tion and growth, we knocked down CDK9 expression with a CDK9-
specific siRNA and investigated the change in osteosarcoma cell viability
and cell signaling pathways. After transfection with increasing concen-
trations of CDK9 siRNA for 3 days, therewas a dose-dependent decrease
in the cell viability of both U2OS and KHOS cells, whichwas not present
in the nonspecific siRNA transfected cells and the cell only control
(Fig. 5A and B). In addition to this, CDK9 siRNA transfection significantly
inhibited CDK9 expression as determined by Western blotting and im-
munofluorescence assays (Supplementary Figs. S2 and S3A and B). Si-
lencing of CDK9 with siRNA inhibited the CDK9 signaling pathway in a
dose-dependent manner, as indicated by the reduced expression of
phosphorylated RNAPII ser2 as well as MCL-1 and BIRC5, while total
RNAPII expression did not markedly change (Fig. 5C and D).
Table 1
The relationship between CDK9 expression and clinicopathological features of osteosar-
coma patients.
Clinicopathological
features
Number
of
cases
CDK9
Expression
low
CDK9
expression
high
P value
(n, %) (n, %) (n, %)
All patients 70(100) 23 (32.9) 47(67.1)
Age, year
≤18 20(28.6) 5 (25.0) 15(75.0) 0.1719
N18 50(71.4) 18 (36.0) 32(64.0)
Gender
Male 46(65.7) 15(32.6) 31(67.4) 0.6799
Female 24(34.3) 8(33.3) 16(66.7)
Tumor site
Femur 33(47.1) 10(30.3) 23(69.7) 0.9945
Tibia 13(18.6) 4(30.8) 9(69.2)
Humeral bone 8 (11.4) 3(37.5) 5(62.5)
Other 16(22.9) 6(37.5) 10(62.5)
Metastasis
Absent 13(18.6) 8(61.5) 5(38.5) 0.0064a
Present 57(81.4) 14(24.6) 43(75.4)
Recurrence
Absent 47(67.1) 16(34.0) 31(66.0) 0.9899
Present 23(32.9) 7(30.4) 16(69.6)
a Statistically significant.
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osteosarcomas
Kinase inhibitors are the backbone for many current targeted cancer
therapies. However, due to the heterogeneity of the disease, kinaseFig. 2. The correlation between CDK9 expression and clinicopathological characteristics and
primary tumor tissues (patients without metastasis/recurrence of disease) and tissues from p
scores between osteosarcoma tissues of patients with metastatic (including patients with
metastatic disease (based on the disease status of patients at the end of follow-up time). (C)
survivor osteosarcoma tissues. (D) Kaplan-Meier overall-survival curve of patients with osteos
high-expression group (staining score ≥ 3+). Compared with the low-expression group, the p
free survival curves of patients with osteosarcoma that were sub-grouped as either CDK9 low
Comparison between the two groups, patients with high CDK9 expression had worse disease-based therapeutic options have not yet been established for osteosar-
coma treatment. After validating the expression and clinical signifi-
cance of CDK9 in patients osteosarcoma samples, we further assessed
the effect of CDK9 inhibition on the proliferation of osteosarcoma
cells. Cell viability was decreased in a dose-dependent manner in
both osteosarcoma cell lines U2OS and KHOS, with the IC50 values
for LDC067 at 5.80 μM and 6.50 μM, respectively. The effect of treat-
ment with the increasing concentrations of LDC067 for 5 days was an-
alyzed (Fig. 6A and B). Similarly, the morphologic changes and a
reduction of the viable cell number were observed with an increase
in the concentration of LDC067 in osteosarcoma cell lines, when
treated for 72 h (Fig. 6C).
To investigate theCDK9 cell signalingpathway,wemeasured the ex-
pression of several CDK9 downstream target proteins following LDC067
treatment. After incubation of the cell lines with 2.5, 5, 10, and 20 μM
LDC067 for 48 h, expression of RNAPII ser2, the major downstream tar-
get of CDK9, and the expression of anti-apoptotic proteins, MCL-1 and
BIRC5, were significantly decreased in a dose-dependent manner,
whereas the expression of total RNAPII did not significantly change
(Fig. 6D, E, F, and G). Importantly, LDC067 only inhibits CDK9 activity,
but not its expression, as demonstrated by Western blotting (Fig. 6D,
E, F, and G). Furthermore, a flow cytometry analysis was performed to
evaluate cellular apoptosis induced by inhibiting CDK9 activity. Com-
pared with the untreated cells, the apoptosis rates of U2OS and KHOS
cells, after 10 μM LDC067 treatment, were significantly increased (Sup-
plementary Fig. S4).
We next assessed the effect of LDC067 on the colony forming ability
of osteosarcoma cells using a clonogenic assay. The clonogenicity of
U2OS and KHOS, when treated with LDC067, was reduced in a dose-
dependent manner, compared with untreated cells (Fig. 7A). Cellprognosis of osteosarcoma patients. (A) Distribution of CDK9 immunostaining scores in
atients with metastatic disease. (B) Comparison of CDK9 immunohistochemistry staining
primary metastatic disease and patients who developed metastatic disease) and non-
Comparison of CDK9 immunohistochemistry staining scores between survivor and non-
arcoma were sub-grouped as either CDK9 low-expression group (staining score ≤ 2+) or
atients with high CDK9 staining had a shorter overall survival. (E) Kaplan-Meier disease-
expression group (staining score ≤ 2+) or high expression group (staining score ≥ 3+).
free survival.
Table 2
Univariate and multivariate survival analysis of prognostic factors in osteosarcoma.
Variable Univariate analysis Multivariate analysis
Hazard Ratio 95% CI P value Hazard Ratio 95% CI P value
All patients
Age, year 0.996 0.979–1.014 0.680
≤18
N18
Gender 0.932 0.520–1.663 0.811
Male
Female
Tumor site 1.008 0.353–2.715 0.422
Femur
Tibia
Humeral bone
Other
Metastasis 7.819 4.068–15.030 b0.001a 4.893 2.036-13.162 b0.001a
Present
Absent
Recurrence 1.496 0.822–2.720 0.187
Present
Absent
CDK9 expression 3.411 1.924–6.045 b0.001a 3.568 1.512-8.417 0.004a
High
Low
Response to pre-operative chemotherapy 0.240 0.115–0.499 0.002a 0.128 0.026-0.651 0.008a
Good
Poor
a Statistically significant.
Fig. 3. Association of CDK9 expression with the response of preoperative chemotherapy and tumor necrosis of osteosarcomas patients. (A) Comparison of CDK9 immunostaining scores
between good responders and poor responders osteosarcoma tissues based on the histological necrosis percentage after preoperative chemotherapy. (B) Kaplan-Meier overall survival
curves of patients with osteosarcoma that were sub-grouped as either good or poor responders to preoperative chemotherapy. The overall survival of good responders was better than
poor responders. (C) Inverse correlation between the expression of CDK9 and overall survival of osteosarcoma patients (P b .0001, r = −0.6422, based on the Spearman's rank
correlation). (D) Positive correlation between percent tumor necrosis and overall survival in osteosarcoma patients (P b .0001, r= 0.6630, based on the Spearman's rank correlation).
(E) Inverse correlation between CDK9 expression and overall survival of osteosarcoma patients (P b .0001, r=−0.5884, based on the Spearman's rank correlation).
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Fig. 4. Expression of CDK9 in osteosarcoma cell lines and osteosarcoma patient fresh tissues. (A) Expression levels of CDK9 in osteosarcoma cell lines (U2OS, U2OSR2, KHOS, KHOSR2,
MG63, Saos-2, 143B and MNNG/HOS) were stronger than the expression of CDK9 in the normal osteoblast cell line (HOB-c) measured by Western blotting. (B) Densitometry
quantification of the Western blots of CDK9 from Fig. 4A, presented as relative to tubulin expression. The data represent the mean ± SE of the experiment carried out in triplicate.
(C) CDK9 expression in eight human osteosarcoma fresh tissues measured by Western blotting. (D) Densitometry quantification of the Western blots of CDK9 from Fig. 4C, presented
as relative to tubulin expression. The data represent the mean ± SE of the experiment carried out in triplicate. (E) Confirmation of CDK9 expression in osteosarcoma cell lines by
immunofluorescence with antibodies to CDK9 (green) and Actin (red). Green fluorescence of CDK9 protein was mainly localized in the nucleus of osteosarcoma cells (Scale bar, 50 μm).
189H. Ma et al. / EBioMedicine 39 (2019) 182–193migration and invasion are the crucial steps in the event of cancer me-
tastasis. As TMA results showed that the expression of CDK9was signif-
icantly correlated to metastatic disease in osteosarcoma patients, we
further evaluated the role of CDK9 in osteosarcoma cell migration
in vitro, after exposure to 10 μM of LDC067 for 24, 48, and 72 h. Cell mi-
gration was significantly suppressed both in U2OS and KHOS cells in a
time-dependent manner (Fig. 7B, C, D, and E).
Additionally, to evaluate whether suppression of CDK9 could alter
the tumorigenicity of osteosarcoma in a simulated in vivo environment,
a three-dimension(3D) cell culture was used to test the effect. Observa-
tions of spheroid sizewere recorded at different time points. The spher-
oid diameters in CDK9 inhibitor-treated U2OS and KHOS cells were
significantly smaller than the untreated cells (Fig. 7F and G). After
12 days of 10 μM CDK9 inhibitor treatment, the spheroid diameter of
U2OS cell was 57.4% of the untreated U2OS cell (P b .001, based on the
Independent two-tailed Student t-test) (Fig. 7H). Similar results were
also found in the KHOS cell line, with the diameter of the KHOS spheroid
at 48.8% of the untreated KHOS cell (P b .001, based on the Independent
two-tailed Student t-test) (Fig. 7I).4. Discussion
Previous studies have demonstrated that CDK9 expression is a poor
prognostic factor for the clinical outcomes ofmany tumors [20,21,24]. In
our study, we analyzed the expression of CDK9 in 70 osteosarcoma tis-
sue specimens and, for the first time,we have identified a close relation-
ship between CDK9 expression and poor patient clinical outcomes. TMA
of osteosarcoma tissue samples showed that 95.7% expressed CDK9. No-
tably, 27 of 32 (84.4%) samples frompatientswithmetastatic disease re-
vealed a high expression of CDK9 (staining score ≥ 3+), which was
significantly higher than tumor tissues of patients without metastatic
disease. Additionally, our study revealed that osteosarcoma patients
with high CDK9 expression had a worse overall survival rate and
disease-free survival rate than those patients with low CDK9
expression.
Although the histological response to preoperative chemotherapy
has generally been accepted as one of the most important prognostic
factors of the clinical outcomes of osteosarcoma patients, and is fre-
quently used to guide the choice of postoperative chemotherapy
Fig. 5. CDK9 inhibition by siRNA decreased osteosarcoma cell proliferation by suppression of the RNAPII phosphorylation pathway. Cell viability of (A) U2OS and (B) KHOS, determined by
MTT assays measured at 490 nm after CDK9 siRNA negative control (NC) siRNA transfection. The data is mean ± SE of the 2 experiments carried out in triplicate. The expression of
respective proteins in CDK9-associated signaling pathway was measured by Western blotting in the osteosarcoma cell lines (C) U2OS, and (D) KHOS after 72 h of siRNA transfection.
(** indicates P b .01).
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cent tumor necrosis post-neoadjuvant therapy and associated bio-
marker in patients with osteosarcoma. Patients with a histological
response to preoperative chemotherapy, i.e. ≥90% necrosis (good re-
sponders), have been shown to have a much better survival rate than
those with b90% necrosis (poor responders) [33,36–38]. Therefore, pa-
tients with a tumor necrosis rate of ≥90% should be continued on a sim-
ilar chemotherapy to the preoperative regimen for a likely successful
treatment. However, patients with tumor necrosis rates b90% are at a
much higher risk of metastasis and recurrence even after complete sur-
gical resection of the primary tumor. Although usually a new chemo-
therapy regimen that differs from the preoperative regimen by
combining or replacing new chemotherapeutic agents is applied in
order to improve the outcome of poor responders, the efficacy of these
changed regimens has shown limited benefit for patients [39–42]. Fur-
thermore, the degree of necrosis is usually only known after 8 to
10 weeks of preoperative chemotherapy. In this period, the tumor
cells may develop resistance or metastasize to the lungs if the preoper-
ative chemotherapy is ineffective. Thus, it is necessary to identify thepa-
tients who are likely to not respond to the standard preoperative
treatment at the time of initial diagnosis. In this study, we have demon-
strated that the expression of CDK9 is inversely correlated to the degree
of tumor necrosis that arises post-neoadjuvant chemotherapy, and, im-
portantly, this relates to the clinical prognosis of osteosarcoma patients.
These data indicate that CDK9 can serve as an alternative predictor of
neoadjuvant therapy outcomes (tumor necrosis) and as a prognostic
marker in osteosarcoma.To date, over-expression of CDK9 has been reported in a number of
cancer types [20,43]. Here, we find that CDK9 is also highly expressed
in both osteosarcoma cell lines and in most of the fresh osteosarcoma
tissues, which was consistent with the CDK9 TMA data. We also ex-
plored if the expression of CDK9 played a critical role in osteosarcoma
growth and proliferation. CDK9 is a transcription factor reported to reg-
ulate the transcription of RNAPII, the key enzyme involved in the syn-
thesis of mRNA [19,29]. To verify the biological role of CDK9 in
osteosarcoma cell growth and proliferation, we conducted a knock-
down analysis using a specific siRNA to CDK9. The results demonstrated
a reduction in the cell growth and viability of U2OS and KHOS osteosar-
coma cells when CDK9 was silenced.
As CDK9 inhibitors have recently been assessed in preclinical studies
for the treatment of hematologic cancers [44,45], we also performed
in vitro CDK9 loss-of-function studies to assess cell proliferation and
growth of osteosarcoma cells. We found that the inhibition of CDK9 ac-
tivity also decreased osteosarcoma cell growth and proliferation in
dose-dependent manner. The transcriptional function of CDK9 requires
phosphorylation on the ser2 of the CTD of RNAPII during elongation
[46,47]. Moreover, LDC067 has been confirmed to target the ser2 of
the RNAPII CTD, preventing phosphorylation and inducing apoptosis
[31]. To further characterize the function of CDK9 in osteosarcoma cell
survival and proliferation, we also investigated how interrupting the
CDK9-signaling pathway impacts the target genes RNAPII ser2 in osteo-
sarcoma cells. We found that siRNA and LDC067 both reduced the
downstream phosphorylation of RNAPII ser2 and decreased expression
of the anti-apoptotic proteins, BIRC5 andMCL-1. As anticipated, we also
Fig. 6. Effects of the CDK9 inhibitor LDC067 on the expression of CDK9 and cell growth in osteosarcoma cell lines. LDC067, at the indicated concentrations, inhibited osteosarcoma cell
proliferation in (A) U2OS, and (B) KHOS cell lines, which was determined by MTT assays. The data represent the mean ± SE of 2 experiments carried out in triplicate. (C) Microscopy
images of morphologic changes and a reduction in cells number after 72 h of LDC067 treatment (Scale bar, 100 μm). (D) The expression of proteins involved in the CDK9-signaling
pathway in the U2OS osteosarcoma cell line was examined by Western blotting after 48 h of LDC067 treatment. (E) Semiquantitative analysis of Fig. 6D densitometry relative to
tubulin. The data represent the mean ± SE of the experiment carried out in triplicate. (F) The expression of proteins involved in the CDK9-signaling pathway in the KHOS
osteosarcoma cell line was examined by Western blotting after 48 h of LDC067 treatment. (G) Semiquantitative analysis of Fig. 6F densitometry relative to tubulin. The data are mean
± SE of the experiment carried out in triplicate.
191H. Ma et al. / EBioMedicine 39 (2019) 182–193confirmed that LDC067 did not alter the expression of CDK9. Inhibition
of CDK9 has been shown to be an effective anti-cancer strategy by
blocking transcriptional elongation, thereby suppressing the expression
of anti-apoptotic proteins, such as MCL-1, resulting in the induction of
apoptosis in cancer cells [48]. Previous reports have demonstrated
that chronic lymphocytic leukemia cells treated with a CDK9 inhibitor
also suppressed expression of MCL-1 [31,49]. Therefore, our results in
osteosarcomas are compatible with leukemia cells, in which CDK9 inhi-
bition led to a decrease in the expression of anti-apoptotic proteins and
induction of apoptosis.
Clonogenic assays are an in vitro cell survival assay based on the abil-
ity of a single cell to grow colonies [50,51]. The size and number of col-
onies in osteosarcoma cells were reduced in a dose-dependent manner
with LDC067 treatment.While newer treatments have improved osteo-
sarcoma patient survival, the high incidence of lung metastasis means
the mortality rate still remains very high [1,52]. CDK9 has been con-
firmed as a target gene, suppressing tumor cell proliferation, migration
and invasion [53,54]. As CDK9 was expressed highly in 84.4% of the tis-
sues taken from osteosarcoma patients with metastatic disease, wefurther investigated the role of CDK9 in osteosarcoma cell migration
in vitro by treating with LDC067. The cell migration activities were sig-
nificantly suppressed both in U2OS and KHOS cells after LDC067 treat-
ment in a time-dependent manner. Previous studies have shown that
in triple negative breast cancer cell lines treatmentwith a CDK2/9 inhib-
itor resulted in decreased cell migration through a reduction in the
phosphorylation of CDK-mediated Smad3 [55]. Accordingly, it is possi-
ble that the mechanism by which inhibition of CDK9 leads to decreased
cell migration in osteosarcomasmay also be through the suppression of
Smad3 phosphorylation, which warrants further investigation. A more
recent study has revealed that treatment of MYC-amplified and CDK9
overexpressing patient-derived tumor xenografts (PDTX) osteosarcoma
mousemodels, with amulti-CDK inhibitor, resulted in decreased tumor
growth [56]. Similar results have been demonstrated with the multi-
CDK inhibitor, Flavopiridol, targeting CDK1, 2, 6, 7 and 9, which de-
creases metastasis and cell survival in osteosarcomas [57]. Recently, an-
other novel highly selective CDK9 inhibitor, MC180295, shown broad
anti-cancer activity in vitro and demonstrated efficacy against lung can-
cer in vivo [25]. As 3D cell models have been authenticated to be more
Fig. 7. CDK9 inhibition reduced osteosarcoma cell clonogenicity and migration in vitro and decreased the spheroid diameter of osteosarcoma cell lines in a 3D cell culture.
(A) Representative results of colony formation in U2OS and KHOS. The numbers of colonies and their sizes were markedly decreased in cells treated with LDC067. Representative
images of (B) U2OS, and (C) KHOS cell migration after LDC067 treatment for 24 h, 48 h, and 72 h. Cell migration distance of osteosarcoma cell lines (D) U2OS, and (E) KHOS were
measured after 10 μM of LDC067 treatment. Spheroid formation of (F) U2OS, and (G) KHOS were significantly smaller than untreated cells at all observation points. Cells fluorescence
images of spheroid formation were taken after 12 days of cultivation. The curves of relative spheroid diameter of (H) U2OS, and (I) KHOS treated with CDK9 inhibitor compared with
untreated cells at all observation points. The data are mean ± SE of the 2 experiments carried out in triplicate (Scale bar, 100 μm). (** indicates P b .01).
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[32,58], we further validated the effect of CDK9 inhibition on cell prolif-
eration using 3D cell cultures to simulate the in vivo tumor environ-
ment. Furthermore, we also found that the spheroid diameter of cells
treated by the CDK9 inhibitor was significantly decreased compared
with the untreated cells. Collectively, these results indicate that CDK9
plays a crucial role in the growth and proliferation of osteosarcoma cells.
In conclusion, our study demonstrated that the level of CDK9 expres-
sion is associated with the clinical prognosis of patients with osteosar-
coma. CDK9 inhibition decreases osteosarcoma cell growth and
proliferation by preventing RNAPII phosphorylation. These findings
suggest that CDK9 may be a potential novel molecular biomarker for
the early detection of disease and also may offer to be an effective ther-
apeutic target in osteosarcoma.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2018.12.022.
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